Abstract:Osteoporosis is a serious health issue among aging postmenopausal women. The majority of postmenopausal women with osteoporosis have bone loss related to estrogen deficiency. The rapid bone loss results from an increase in bone turnover with an imbalance between bone resorption and bone formation. Osteoporosis can also result from excessive glucocorticoid usage, which induces bone demineralization with significant changes of spatial heterogeneities of bone at microscale, indicating potential risk of fracture. This review is a summary of current literature about the molecular mechanisms of actions, the risk factors, and treatment of estrogen deficiency related osteoporosis (EDOP) and glucocorticoid induced osteoporosis (GIOP). Estrogen binds with estrogen receptor to promote the expression of osteoprotegerin (OPG), and to suppress the action of nuclear factor-κβ ligand (RANKL), thus inhibiting osteoclast formation and bone resorptive activity. It can also activate Wnt/β-catenin signaling to increase osteogenesis, and upregulate BMP signaling to promote mesenchymal stem cell differentiation from pre-osteoblasts to osteoblasts, rather than adipocytes. The lack of estrogen will alter the expression of estrogen target genes, increasing the secretion of IL-1, IL-6, and tumor necrosis factor (TNF). On the other hand, excessive glucocorticoids interfere the canonical BMP pathway and inhibit Wnt protein production, causing mesenchymal progenitor cells to differentiate toward adipocytes rather than osteoblasts. It can also increase RANKL/OPG ratio to promote bone resorption by enhancing the maturation and activation of osteoclast. Moreover, excess glucocorticoids are associated with osteoblast and osteocyte apoptosis, resulting in declined bone formation. The main focuses of treatment for EDOP and GIOP are somewhat different. Avoiding excessive glucocorticoid use is mandatory in patients with GIOP. In contrast, appropriate estrogen supplement is deemed the primary treatment for females with EDOP of various causes. Other pharmacological treatments include bisphosphonate, teriparatide, and RANKL inhibitors. Nevertheless, more detailed actions of EDOP and GIOP along with the safety and effectiveness of medications for treating osteoporosis warrant further investigation.

Pituitary Disorders and Osteoporosis

Diagnosis and therapeutic approach to bone health in patients with hypopituitarism

Focusing on Osteopenia/Osteoporosis

Neuroendocrinology of bone

Skeletal fragility in pituitary disease: how can we predict fracture risk?

Cushing's disease and bone

Secondary osteoporosis - an endocrinological approach focusing on underlying mechanisms

Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover

Musculoskeletal complications of Cushing syndrome

Vitamin D in pituitary driven osteopathies

Beyond the Surface: Uncovering Secondary Causes of Osteoporosis for Optimal Management

Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview

Osteoporosis complicating some inborn or acquired diseases.

Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes

Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer

Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly

Primary Aldosteronism and Bone Metabolism: A Systematic Review and Meta-Analysis

Secondary Osteoporosis and Metabolic Bone Diseases

The Influence of Pituitary, Adrenal, and Parathyroid Hormones on Hemostasis and Thrombosis

Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people

Glucocorticoid-Associated Osteoporosis in Chronic Inflammatory Diseases: Epidemiology, Mechanisms, Diagnosis, and Treatment